ROBOSENSE
RoboSense, a leading automotive LiDAR manufacturer, announced today that it has obtained the IATF 16949 certificate in the automotive field, which now fully qualifies it to supply to automotive customers. RoboSense’s LiDAR production line obtained the IATF 16949 Letter of Conformity in December, which has accelerated partnerships of automotive-grade LiDAR serial productions with major OEMs and Tier 1s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200207005157/en/
Developed by the IATF (International Automotive Task Force) and submitted to the International Organization for Standardization (ISO) for approval and publication, IATF 16949 is the most widely used global quality management standard for the automotive industry. In addition, the high quality management that IATF 16949 offers utilizes 5 tools (APQP/FMEA/MSA/SPC/PPAP) as part of their application assessment.
Dr. LeiLei Shinohara, the Co-partner and Vice President of RoboSense, said, "IATF16949 requires extremely high production consistency, and emphasizes various product reliability metrics. It recognizes the RoboSense design, research and development, and production processes. It also indicates that RoboSense has achieved a new milestone of complete readiness for serial mass production of automotive LiDARs, including the latest solid-state smart LiDAR "RS-LiDAR-M1".”
RoboSense's "125-layer equivalent" solid-state LiDAR "RS-LiDAR-M1" was officially released in January 2020 as the world’s first MEMS LiDAR to obtain IATF6949 for its production line. Its production was carried out under the IATF16949 quality management system.
The product development of "RS-LiDAR-M1" followed the APQP and A-SPICE as the basis for the project management and product development process. During production, RoboSense fully implemented the IATF16949 quality management system and ISO26262 functional safety standards. By combining ISO16750 test requirement and other automotive-grade reliability specifications with these systems, the accuracy of the RS-LiDAR-M1 product can be verified.
MEMS mirror is the core component in RS-LiDAR-M1. According to the AEC-Q100 standard, combining the characteristics of MEMS micro-mirror, a total of ten verification test groups were designed, covering factors such as: temperature, humidity, packaging process, electromagnetic compatibility, mechanical vibration and shock, and aging. The cumulative test time for all test samples has now exceeded 100,000 hours. Furthermore, the longest-running prototype has been tested for more than 300 days, while the total road test mileage has exceeded 150,000 kilometers with no degradation found in various testing scenarios.
In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the required standards and the final mass-produced RS-LiDAR-M1 will adapt to all climate and working conditions.
RoboSense continues to optimize the LiDAR performance in order to lead the way towards a driverless future. On September 25, 2019, RoboSense partnered with First Automobile Works (FAW), the world's leading automotive OEM, to include RS-LiDAR-M1 as a core component in FAW's proprietary next-generation autonomous driving system development. On January 8, 2020, during CES2020, RoboSense cooperated with Freetech, the leading ADAS solution provider, on the serial production of the smart multi-sensor fusion solution.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems. By incorporating LiDAR sensors, AI algorithms and IC chipsets, conventional 3D LiDAR sensors are transformed to full data analysis and comprehension systems. The company's mission is to provide outstanding hardware and artificial intelligence capabilities to deliver smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
About IATF
IATF members include BMW Group, Daimler AG, FCA, Ford Motor Company, General Motors Company, Jaguar Land Rover (JLR) Limited, PSA Group, Renault, Volkswagen AG and the vehicle manufacturers respective trade associations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005157/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom